Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 28

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Obesity

Not yet recruiting

Study of the effectiveness and safety of tirzepatide for treating obesity in patients waiting for a liver transplant

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Institute For Clinical And Experimental Medicine

Hypoparathyroidism

Not yet recruiting

A study to evaluate the safety and effects of palopegteriparatide in adolescents with chronic hypoparathyroidism

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Palopegteriparatide
  • Sponsor:Ascendis Pharma Bone Diseases A/S

Osteoporosis postmenopausal

Not yet recruiting

Comparing the effect of romosozumab and denosumab on coronary artery damage in women with postmenopausal osteoporosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Denosumab
  • Sponsor:Ospedale Galeazzi S.p.A.

Diabetic neuropathy

Not yet recruiting

Study of the effectiveness and safety of alpha-lipoic acid and benfotiamine for the treatment of symptoms in patients with diabetic neuropathy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Benfotiamine
  • Sponsor:Woerwag Pharma GmbH & Co. KG

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ponsegromab
  • Sponsor:Pfizer Inc.

Endocrine ophthalmopathy

Not yet recruiting

A study testing teprotumumab compared to placebo in adult patients with moderate-to-severe active thyroid eye disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teprotumumab
  • Sponsor:Horizon Therapeutics USA Inc.

Endocrine ophthalmopathy+1

Not yet recruiting

A study to test if atorvastatin can prevent eye disease in patients newly diagnosed with Graves' disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Region Skane

Type 1 diabetes mellitus+1

Not yet recruiting

A study testing dapagliflozin and SC0062 together compared to SC0062 alone in adults with type 1 diabetes and chronic kidney disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Diabetes mellitus+2

Not yet recruiting

A Study of Semaglutide for Diabetic Patients with Heart Attack or Unstable Angina to Measure Changes in Coronary Artery Plaque Using Imaging

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Azienda Ospedaliero-Universitaria Maggiore Della Carita

Type 2 diabetes mellitus

Not yet recruiting

Study of semaglutide and dapagliflozin effects on heart muscle insulin resistance in patients with type 2 diabetes

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Fabry's disease

Not yet recruiting

A Study of Migalastat Safety and Effects in Children Aged 2 to 12 Years with Fabry Disease and Suitable Gene Changes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Amicus Therapeutics Inc.

Obesity

Not yet recruiting

Study comparing rocuronium dosing based on ideal versus real body weight for airway tube placement in patients with severe obesity

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:UZ Brussel

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.